ACC Updated Heart Failure Care Guidelines

The American College of Cardiology has released an updated consensus pathway for managing heart failure with preserved ejection fraction.

Updated on Oct. 14, 2026 in Heart Disease

ACC Updated Heart Failure Care Guidelines

Live Poll

Do you trust that updated medical guidelines effectively improve the accuracy of complex disease diagnoses?

The American College of Cardiology has published a new expert consensus decision pathway for heart failure with preserved ejection fraction. The update characterizes the condition as a multisystem syndrome driven by metabolic dysfunction and inflammatory pathways.

Why it matters

Recent research supported expanding the recommended medication classes, as clinicians often focused on individual symptoms rather than the underlying diagnosis. This update provides a structured approach to ensure comprehensive treatment for the syndrome.

The diagnostic approach outlines 3 distinct steps for patient assessment. The consensus provides specific titration and dosing strategies for SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal mineralocorticoid receptor agonists.

The players

American College of Cardiology

The American College of Cardiology is a professional medical society that establishes clinical guidelines and educational standards for cardiovascular practitioners.

The details

The diagnostic process mandates that clinicians evaluate patients for noncardiac mimics like kidney disease and obesity, as well as cardiac mimics such as aortic stenosis and cardiac amyloidosis. By identifying these conditions early, providers can better implement tailored management plans for the syndrome.

The original expert consensus decision pathway was published in 2023.
The updated expert consensus decision pathway was published in October 2026.

Health Landscape

The updated consensus follows the 2023 American College of Cardiology expert consensus decision pathway. This update marks a significant evolution in medical science by shifting the focus from individual symptoms toward managing the condition as a systemic syndrome.

Patients may see changes in their treatment regimens as clinicians begin incorporating SGLT2 inhibitors and GLP-1 receptor agonists based on the new recommendations. These updates provide a clearer pathway for distinguishing between heart failure and other potential cardiac or noncardiac conditions.

The takeaway

Patients should consult their cardiologists to determine if these updated treatment strategies apply to their specific health profile. The guidelines highlight the importance of investigating underlying metabolic or inflammatory issues rather than merely treating isolated cardiac symptoms.